VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.
The BiTAC-ADC platform represents a novel approach to antibody-drug conjugates (ADCs), a class of cancer therapies that deliver potent toxins directly to tumor cells. Traditional ADCs, while effective, can cause off-target toxicity because the toxin is always active once administered. VERAXA’s technology addresses this by using two separate components that only combine and become active in the tumor microenvironment, potentially reducing side effects.
According to the company, the in vitro studies used breast cancer cell lines and healthy cells to test selectivity. The BiTAC-ADCs showed significant killing of cancer cells in 3D spheroid models, which better mimic solid tumors, while leaving healthy cells largely unaffected. This selectivity is a key advantage over conventional ADCs.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs, guided by quality-by-design principles.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. The full press release can be viewed at https://ibn.fm/QiPhH.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech Reports Proof-of-Concept Data for Tumor-Restricted BiTAC-ADC Cancer Therapy Platform.